{"id":"W2557666746","doi":"10.1016/s1470-2045(16)30559-9","title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1200,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"Cancer Research UK; Clovis Oncology; Ovarian Cancer Research Fund; Stand Up To Cancer; Healthway; U.S. Department of Defense; National Ovarian Cancer Coalition; Ovarian Cancer Research Fund Alliance; American Association for Cancer Research","keywords":"Open label; Oncology; Medicine; Internal medicine; Ovarian carcinoma; Platinum; Ovarian cancer; Clinical trial; Cancer; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1468834883678543,"score_gpt":0.4311228869311657,"score_spread":0.2842393985633114,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}